Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity

T. Etrych, J. Strohalm, L. Kovář, M. Kabešová, B. Říhová, K. Ulbrich

. 2009 ; 140 (1) : 18-26.

Language English Country Netherlands

Document type Evaluation Study, Research Support, Non-U.S. Gov't

E-resources

NLK ScienceDirect (archiv) from 1993-01-01 to 2009-12-31

Synthesis, physicochemical and biological properties and preliminary anticancer activity of new star-shaped polymer-doxorubicin (DOX) conjugates targeted with anti-CD20 monoclonal antibody were investigated. Mild reduction of antibody (Ab) with dithiothreitol (DTT) resulted in introduction of thiol groups into Ab. Polymer precursors used for the synthesis of the conjugates were based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers with a functional group at the polymer chain end. The copolymers were linked to the thiol groups of the reduced Ab via one-point attachment forming a star-shaped structure with central antibody surrounded by hydrophilic polymer chains. Neither reduction nor polymer modification of Ab influenced binding activity of the Ab to its specific cancer cell membrane antigen as it was confirmed in vitro by standard flow cytometry. The anticancer drug DOX was attached to the HPMA copolymer chain in an Ab-polymer system via a pH-labile hydrazone linkage or via an oligopeptide sequence degradable by lysosomal enzymes. Such Ab-polymer-DOX conjugates were fairly stable in aqueous solution at pH 7.4 and the drug was readily released in mildly acid environment at pH 5-5.5 by hydrolysis of hydrazone bond or more slowly by enzymolysis with lysosomal enzymes. The cytostatic activity of the anti-CD20 monoclonal Ab-targeted conjugates tested on several CD20-positive or negative human and mouse cancer cell lines confirmed considerable targeting capacity of the monoclonal Ab after its binding to the polymer carrier. New method of synthesis of star antibody-targeted polymer-drug conjugates with pH-controlled drug release described in this paper opens new perspectives for development of new therapeutics intended for cancer therapy.

000      
03970naa 2200565 a 4500
001      
bmc11022205
003      
CZ-PrNML
005      
20121129101036.0
008      
110729s2009 ne e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Etrych, Tomáš $7 xx0068504
245    10
$a HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity / $c T. Etrych, J. Strohalm, L. Kovář, M. Kabešová, B. Říhová, K. Ulbrich
314    __
$a Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic. etrych@imc.cas.cz
520    9_
$a Synthesis, physicochemical and biological properties and preliminary anticancer activity of new star-shaped polymer-doxorubicin (DOX) conjugates targeted with anti-CD20 monoclonal antibody were investigated. Mild reduction of antibody (Ab) with dithiothreitol (DTT) resulted in introduction of thiol groups into Ab. Polymer precursors used for the synthesis of the conjugates were based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers with a functional group at the polymer chain end. The copolymers were linked to the thiol groups of the reduced Ab via one-point attachment forming a star-shaped structure with central antibody surrounded by hydrophilic polymer chains. Neither reduction nor polymer modification of Ab influenced binding activity of the Ab to its specific cancer cell membrane antigen as it was confirmed in vitro by standard flow cytometry. The anticancer drug DOX was attached to the HPMA copolymer chain in an Ab-polymer system via a pH-labile hydrazone linkage or via an oligopeptide sequence degradable by lysosomal enzymes. Such Ab-polymer-DOX conjugates were fairly stable in aqueous solution at pH 7.4 and the drug was readily released in mildly acid environment at pH 5-5.5 by hydrolysis of hydrazone bond or more slowly by enzymolysis with lysosomal enzymes. The cytostatic activity of the anti-CD20 monoclonal Ab-targeted conjugates tested on several CD20-positive or negative human and mouse cancer cell lines confirmed considerable targeting capacity of the monoclonal Ab after its binding to the polymer carrier. New method of synthesis of star antibody-targeted polymer-drug conjugates with pH-controlled drug release described in this paper opens new perspectives for development of new therapeutics intended for cancer therapy.
590    __
$a bohemika - dle Pubmed
650    _2
$a akrylamidy $x chemie $7 D000178
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorová antibiotika $x chemie $7 D000903
650    _2
$a monoklonální protilátky $x imunologie $7 D000911
650    _2
$a Burkittův lymfom $x farmakoterapie $x metabolismus $7 D002051
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cytostatické látky $x metabolismus $7 D054697
650    _2
$a doxorubicin $x chemie $7 D004317
650    _2
$a nosiče léků $x chemická syntéza $x chemie $7 D004337
650    _2
$a lékové transportní systémy $7 D016503
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    _2
$a lidé $7 D006801
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a lymfom T-buněčný $x farmakoterapie $x metabolismus $7 D016399
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methakryláty $x chemie $7 D008689
650    _2
$a myši $7 D051379
650    _2
$a chemické modely $7 D008956
650    _2
$a molekulová hmotnost $7 D008970
650    _2
$a polymery $x chemie $7 D011108
650    _2
$a rozpustnost $7 D012995
650    _2
$a voda $x chemie $7 D014867
655    _2
$a hodnotící studie $7 D023362
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Strohalm, Jiří $7 xx0109134
700    1_
$a Kovář, Lubomír $7 xx0126758
700    1#
$a Kabešová, Martina. $7 _AN067038
700    1_
$a Říhová, Blanka, $d 1942- $7 jo20000073671
700    1_
$a Ulbrich, Karel, $d 1947- $7 jo2004259877
773    0_
$t Journal of Controlled Release $w MED00002621 $g Roč. 140, č. 1 (2009), s. 18-26
910    __
$a ABA008 $b x $y 2
990    __
$a 20110729094053 $b ABA008
991    __
$a 20121129101104 $b ABA008
999    __
$a ok $b bmc $g 867038 $s 732098
BAS    __
$a 3
BMC    __
$a 2009 $x MED00002621 $b 140 $c 1 $d 18-26 $m Journal of controlled release $n J Controlled Release
LZP    __
$a 2011-4B09/jvme

Find record